Table 3.
Results from the random parameter logit model
| Attribute | Level | Coefficient estimate (95% CI)a | P value from previous level | Significant SDb |
|---|---|---|---|---|
| Effectiveness | 25% Reduction | − 2.165 (− 2.519, − 1.811) | – | – |
| 50% Reduction | − 0.206 (− 0.360, − 0.052) | 0.009 | No | |
| 75% Reduction | 0.818 (0.615, 1.020) | < 0.001 | Yes | |
| 100% Reduction | 1.553 (1.258, 1.847) | < 0.001 | Yes | |
| Pain reduction | Small | − 0.700 (− 0.875, − 0.525) | – | – |
| Moderate | 0.053 (− 0.064, 0.170) | 0.369 | No | |
| Almost complete | 0.647 (0.465, 0.830) | < 0.001 | Yes | |
| Duration of treatment benefit, months | 6 | − 0.092 (− 0.240, 0.056) | – | – |
| 12 | 0.231 (0.103, 0.352) | < 0.001 | No | |
| 24 | − 0.139 (− 0.279, 0.002) | 0.053 | Yes | |
| Annual risk of mild AE | 10% | 0.525 (0.331, 0.719) | – | – |
| 30% | 0.064 (− 0.055, 0.183) | 0.290 | No | |
| 50% | − 0.589 (− 0.797, − 0.381) | < 0.001 | Yes | |
| Annual risk of serious infection | 0.1% | 0.288 (0.138, 0.439) | – | – |
| 1% | 0.218 (0.105, 0.331) | < 0.001 | No | |
| 3% | − 0.506 (− 0.658, − 0.354) | < 0.001 | Yes | |
| Mode of administration | Oral pill, daily | 0.176 (− 0.029, 0.381) | – | – |
| SC injection, bi-weekly | 0.057 (− 0.107, 0.221) | 0.494 | Yes | |
| IV injection, monthly | − 0.233 (− 0.390, − 0.076) | < 0.001 | Yes | |
| K | 26 | |||
| LL | − 1549.7 | |||
| AIC | 3151.5 |
AE adverse event, AIC Akaike information criterion, CI confidence interval, IV intravenous, K number of parameters in the model, LL log-likelihood, SC subcutaneous, SD standard deviation
aA positive (negative) sign for a given level indicates a level has a positive (negative) effect on utility
bSignificance at 5%, SDs correspond to the random component of the model coefficients